פרבה טבע 40 מ"ג - Prava teva 40 mg

Pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolaemia. Pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. Primary prevention of coronary events: In hypercholesterolaemic patients without clinically evident coronary heart disease pravastatin is indicated to: - Reduce the risk of myocardial infarction. - Reduce the risk for revascularization. - Reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. Secondary prevention of cardiovascular events: Atherosclerosis: In hypercholesterolaemic patients with clinically evident coronary artery disease including prior MI Pravastatin is indicated to: - Slow the progression of coronary atherosclerosis.- Reduce the risk of acute coronary events. Myocardial infarction: In patients with previous myocardial infarction and normal cholesterol levels Pravastatin is indicated to: - Reduce the risk of recurrent myocardial infarction.- Reduce the risk of undergoing myocardial revascularization procedures. - Reduce the risk of stroke and transient ischemic attack (TIA). Hypercholesterolaemia and mixed dyslipidemia: Pravastatin is indicated as an adjunct to diet to reduce elevated Total-C, LDL-C and TG levels in patients with primary hypercholesterolaemia and mixed dyslipidemia (Fredrickson type IIa and IIb).